title: Neurotoxicity of the anticoagulant-selective E149A-activated protein C variant after focal ischemic stroke in mice.
abstract: Wild type (WT) activated protein C (APC) and cytoprotective-selective APC variants such as 3K3A-APC (<10% anticoagulant but normal cytoprotective activity) are neuroprotective in murine focal ischemic stroke models. Here we compared the neuroprotective effects of the anticoagulant-selective E149A-APC variant (>3-fold increased anticoagulant activity but defective cytoprotective activities) to those of the cytoprotective-selective 5A-APC variant (<10% anticoagulant activity). After transient distal middle cerebral artery occlusion, mice received a vehicle, E149A-APC or 5A-APC at 0.2mg/kg at 4h after stroke. Treatment with 5A-APC was neuroprotective, as it improved performance on forelimb use asymmetry test and foot fault test (P<0.05), reduced by 48% and 50% the infarct and edema volumes, respectively (P<0.05), and was not associated with an increased risk of bleeding as indicated by normal hemoglobin levels in the ischemic brain at day 7. In contrast, E149A-APC treatment worsened neurological outcome determined by foot fault tests and forelimb use asymmetry tests, and increased significantly by 44% and 60% infarct and edema volume, respectively (P<0.05). At 7days after treatment, E149A-APC compared to vehicle or 5A-APC notably increased by ~5-fold the hemoglobin level in the ischemic hemisphere suggesting it provoked significant intracerebral bleeding. Thus, the enhanced anticoagulant activity of E149A-APC increased post-ischemic accumulation of neurotoxic erythrocyte-derived hemoglobin which likely worsened the neurological and neuropathological outcomes after stroke. Our data emphasize that APC's cytoprotective activities, but not its anticoagulant activity, are key for APC neuroprotection after transient ischemic stroke.
authors.affiliation: Zilkha Neurogenetic Institute, University of Southern California, Keck School of Medicine, Los Angeles, CA, USA.
authors.forename: Yaoming
authors.initials: Y
authors.lastname: Wang
authors.forename: Ranjeet Kumar
authors.initials: RK
authors.lastname: Sinha
authors.forename: Laurent O
authors.initials: LO
authors.lastname: Mosnier
authors.forename: John H
authors.initials: JH
authors.lastname: Griffin
authors.forename: Berislav V
authors.initials: BV
authors.lastname: Zlokovic
mesh_terms: D000818:Animals; D000925:Anticoagulants / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects; D001921:Brain / Q000098:blood supply* / Q000378:metabolism* / Q000473:pathology; D002545:Brain Ischemia / Q000150:complications*; D014644:Genetic Variation; D006454:Hemoglobins / Q000378:metabolism; D008297:Male; D051379:Mice; D018696:Neuroprotective Agents / Q000494:pharmacology; D011486:Protein C / Q000235:genetics / Q000494:pharmacology*; D015427:Reperfusion Injury / Q000188:drug therapy / Q000378:metabolism; D020521:Stroke / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology
chemical_list: D000925:Anticoagulants; D006454:Hemoglobins; D018696:Neuroprotective Agents; D011486:Protein C
references.citation: Am J Respir Cell Mol Biol. 2011 Sep;45(3):632-41
references.pmid: 21257925
references.citation: J Clin Invest. 2009 Nov;119(11):3437-49
references.pmid: 19841542
references.citation: Hum Genet. 2013 Jan;132(1):69-77
references.pmid: 22976599
references.citation: Brain Res. 2010 Aug 6;1347:125-31
references.pmid: 20513369
references.citation: Biochemistry. 1993 Nov 30;32(47):12656-63
references.pmid: 8251484
references.citation: Blood. 2007 Apr 15;109(8):3161-72
references.pmid: 17110453
references.citation: J Clin Invest. 2010 Sep;120(9):3167-78
references.pmid: 20714108
references.citation: Blood. 2004 Sep 15;104(6):1740-4
references.pmid: 15178575
references.citation: Trends Neurosci. 2011 Apr;34(4):198-209
references.pmid: 21353711
references.citation: Int J Hematol. 2012 Apr;95(4):333-45
references.pmid: 22477541
references.citation: Eur J Neurosci. 2009 Mar;29(6):1119-30
references.pmid: 19302148
references.citation: Nat Med. 2003 Mar;9(3):338-42
references.pmid: 12563316
references.citation: Stroke. 1997 Nov;28(11):2296-302
references.pmid: 9368579
references.citation: Thromb Haemost. 2012 May;107(5):951-61
references.pmid: 22370814
references.citation: Stroke. 2009 May;40(5):1864-9
references.pmid: 19057019
references.citation: Nat Med. 2006 Nov;12(11):1278-85
references.pmid: 17072311
references.citation: Blood. 2012 Dec 20;120(26):5237-46
references.pmid: 23149848
references.citation: J Cereb Blood Flow Metab. 2009 Feb;29(2):385-97
references.pmid: 18985053
references.citation: Stroke. 1999 Mar;30(3):542-5
references.pmid: 10066849
references.citation: J Biol Chem. 2002 Aug 9;277(32):28836-40
references.pmid: 12063259
references.citation: J Clin Invest. 1999 Dec;104(11):1613-20
references.pmid: 10587525
references.citation: Blood Cells Mol Dis. 2006 Mar-Apr;36(2):211-6
references.pmid: 16464623
references.citation: Brain. 2005 Jan;128(Pt 1):52-63
references.pmid: 15509618
references.citation: Stroke. 2004 Nov;35(11):2571-5
references.pmid: 15472083
references.citation: Nat Med. 2004 Dec;10(12):1379-83
references.pmid: 15516929
references.citation: J Neurochem. 2009 Apr;109(1):116-24
references.pmid: 19166505
references.citation: Nat Med. 2012 Jul;18(7):1123-9
references.pmid: 22729286
references.citation: J Biol Chem. 2007 Nov 9;282(45):33022-33
references.pmid: 17872949
references.citation: J Exp Med. 2007 Oct 1;204(10):2439-48
references.pmid: 17893198
references.citation: Blood. 2009 Jun 4;113(23):5970-8
references.pmid: 19244160
references.citation: Stroke. 2012 Sep;43(9):2444-9
references.pmid: 22811462
references.citation: Ann Neurol. 2005 Sep;58(3):474-7
references.pmid: 16130108